Phaseline

Companies › Celcuity

Celcuity: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Gedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03911973GedatolisibPhase 1TNBC - Triple-Negative Breast CancerOncologyJul 2024
NCT05501886GedatolisibPhase 3Breast CancerOncologyDec 2026
NCT06190899GedatolisibPhase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)OncologyJan 2028
NCT03675893GedatolisibPhase 2Endometrial CancerOncologyAug 2028
NCT06757634GedatolisibPhase 3Breast CancerOncologyMar 2029

From the company's SEC filings

Cash and short-term investments of $643m on 2026-09-30; operating cash outflow about $237m a year; runway about 32 months at that burn, to Jun 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MTOR (1) PIK3R1 (1) PIK3CB (1) PIK3CG (1) PIK3CA (1)

Companies with the same targets

Eli Lilly Restorbio Sovargen Faeth Therapeutics iVascular S.L.U. Palvella Therapeutics Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca ThromBio

Companies built like this

BioLineRx Faeth Therapeutics SecuraBio Olema Pharmaceuticals LaNova Medicines Zhejiang

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.